Probiodrug Ag

Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V.

Vivoryon Therapeutics N.v.

Vivoryon Therapeutics Ag

Daniel Ramsbeck

Ulrich Heiser

Hans-Ulrich Demuth

Stephan Schilling

Torsten Hoffmann

Mirko Buchholz

Livia Boehme

Robert Sommer

Antje Meyer

Andre Johannes Niestroj

Dagmar Schlenzig

Holger Cynis

Michael Wermann

Anke Piechotta

Linda Liebe

Stephen Schilling

Christian Jäger

Miriam Linnert

Stefanie Geissler

Diane Meitzner

Anja Schulze

Marvin Hempel

Kathrin Tan

André J Niestroj

The present invention relates to novel hydroxamic acid derivatives as inhibitors of meprin β and/or α, pharmaceutical compositions comprising such compounds, methods for treatment or prophylaxis of diseases or conditions, especially such that are related to meprin β and/or α, and compounds and pharmaceutical compositions for use in such methods.

Inhibitors of meprin α and β

The present invention relates to novel compounds which are particularly useful as inhibitors of bacterial glutaminyl cyclases (bacQC); pharmaceutical compositions comprising such compounds; compounds and/or pharmaceutical compositions for use in methods for treatment, in particular for use in the treatment of periodontitis and related conditions; as well as to crystals comprising bacterial glutaminyl cyclases, methods for identifying candidate compounds which may associate with the binding pocket of a bacQC and/or are bacQC inhibitors.

Inhibitors of bacterial glutaminyl cyclases for use in the treatment of periodontal and related diseases

The present invention relates to novel hydroxamic acid derivatives as inhibitors of meprin &#x3b2; and/or &#x3b1;, pharmaceutical compositions comprising such compounds, methods for treatment or prophylaxis of diseases or conditions, especially such that are related to meprin &#x3b2; and/or &#x3b1;, and compounds and pharmaceutical compositions for use in such methods.

Inhibitors of meprin &#x3b1; and &#x3b2;

The invention relates to novel pyrrolidine derivatives of formula (I): wherein R, Rand Rare as defined herein, as inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). QC catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamate residues into pyroglutamic acid under liberation of water.

Inhibitors

Radiolabeled glutaminylcyclase (QC) inhibitors as imaging agents, in particular, but not exclusively, as medical imaging agents for the detection of neurological disorders; and pharmaceutical compositions, methods and kits for detecting neurological disorders, using the radiolabeled inhibitors.

Radiolabelled glutaminyl cyclase (QC) inhibitors and uses of same

The invention relates to novel heterocyclic derivatives as inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). QC catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamate residues into pyroglutamic acid under liberation of water.

Inhibitors of glutaminyl cyclase

The present invention relates to compounds of formula (I), combinations and uses thereof for disease therapy, wherein

Radiolabeled glutaminyl cyclase (QC) inhibitors and uses of same

Novel heterocyclic derivatives as inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). QC catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamate residues into pyroglutamic acid under liberation of water.

Novel heterocyclic derivatives of formula (I): or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof, wherein R, n, Rand Rare as defined herein, as inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5).

Compounds of formula (I), combinations and uses thereof for disease therapy, or a pharmaceutically acceptable salt or solvate thereof, including all tautomers, stereoisomers and polymorphs thereof wherein:

Growing community of inventors

Halle/Saale, Germany

Daniel Ramsbeck